-
Mashup Score: 0Subscribe | Blood Cancers Today - 9 month(s) ago
Sign up for Blood Cancers Today eNewsletters to join an extensive community of hematologic oncology professionals and get the latest news and insights from the field.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 2Subscribe | Blood Cancers Today - 10 month(s) ago
Sign up for Blood Cancers Today eNewsletters to join an extensive community of hematologic oncology professionals and get the latest news and insights from the field.
Source: Blood Cancers TodayCategories: Hematologists1, Latest HeadlinesTweet-
Don't miss the new episode of The HemOnc Pulse on July 27 featuring @NitinJainMD discussing venetoclax and combo therapies in #CLL with host @chadinabhan. Subscribe to all of the latest news in heme onc at: https://t.co/aEpyHK3DF2 @MDAndersonNews @SocietyofHemOnc https://t.co/zuo9EnBk8l
-
-
Mashup Score: 0First-in-Human Study Tests CD123-Directed NK-Cell Engager in Relapsed, Refractory AML | Blood Cancers Today - 10 month(s) ago
SAR’579, a trifunctional natural killer (NK)-cell engager, showed “clinical benefit” in patients with relapsed or refractory acute myeloid leukemia (AML).
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
ICYMI: An #ASCO2023 presentation by @A_Stein_AHC of @cityofhope and colleagues outlined data from a first-in-human study evaluating SAR’579, a trifunctional NK-cell engager, in patients with relapsed or refractory AML. 📚: https://t.co/CLFOCvYiYq https://t.co/vbAj40TaM8
-
-
Mashup Score: 7
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Source: Blood Cancers TodayCategories: Hem/Oncs, Latest HeadlinesTweet-
Exxcited that after almost a year of planning, #SOHO meeting of hematologic malignancies is coming to MENA region #SOHOMENA with the first #SOHOMENA23 taking place in Lebanon. A true pleasure to co-chair this outstanding program-Agenda to follow soon. https://t.co/y2raCErOx5
-
-
Mashup Score: 0
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
The @SocietyofHemOnc Ambassador Program engages SOHO members worldwide by facilitating regional meetings. With 126 ambassadors in 63 countries, where will SOHO take you? Perhaps Beirut, Lebanon? https://t.co/jHO9LfY5Q7 @DrHKantarjian @SagarLonialMD @Ramikomrokji https://t.co/1gknbaiR0Y
-
-
Mashup Score: 3Panel Discusses Maintenance Therapy and the Changing Landscape for Early-Relapse Multiple Myeloma | Blood Cancers Today - 10 month(s) ago
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
ICYMI: In this video from the myeloma roundtable series, @szusmani of @MSKCancerCenter; @YiLinMDPhD of @MayoClinic; Shambavi Richard, MD of @TischCancer; and @MeeraMohanMD of @MedicalCollege, discuss maintenance therapy strategies for multiple myeloma. https://t.co/esR1qWfYb2 https://t.co/Yj6wNjfhTn
-
-
Mashup Score: 2Prognostic Scoring System Developed for HSCT in Myelofibrosis | Blood Cancers Today - 10 month(s) ago
A prognostic scoring system identified multiple factors associated with survival in patients with myelofibrosis undergoing an allogeneic hematopoietic stem cell transplant (HSCT).
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
A proposed system was prognostic of survival in CIBMTR and EBMT cohorts of patients with myelofibrosis undergoing HSCT, according to a study by Roni Tamari, MD, of @MSKCancerCenter and colleagues. 📚: https://t.co/idMKebHJZO https://t.co/9zOkcNgBkN
-
-
Mashup Score: 0Sagar Lonial, MD, FACP, Talks Multiple Myeloma Highlights from the Summer Conferences | Blood Cancers Today - 10 month(s) ago
Dr. Lonial shares his top highlights in multiple myeloma from the EHA and ASCO meetings.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
ICYMI: BCT Editor-in-Chief @SagarLonialMD of @WinshipAtEmory discusses an #EHA2023 symposium that he took part in and what he sees as the key highlights in multiple myeloma research presented at the 2023 @EHA_Hematology Congress and #ASCO2023. 📺: https://t.co/IGivH0hNly https://t.co/zNcElCBwdk
-
-
Mashup Score: 0Alex Herrera, MD, Discusses His ASCO Plenary Session on SWOG S1826 Findings | Blood Cancers Today - 10 month(s) ago
Alex Herrera, MD, discusses the study of nivolumab plus AVD with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
Still catching up on all the key hem/onc news from #ASCO23? Don't miss this video featuring Alex Herrera, MD, of @cityofhope discussing his #ASCO23 plenary session on the phase III @SWOG S1826 trial with @chadinabhan at the 2023 @ASCO Annual Meeting! 📺https://t.co/VvZ2j7CytM https://t.co/sjfKpm6UCM
-
-
Mashup Score: 0
Sangeetha Venugopal, MD, of the University of Miami, shares her thoughts on results from the phase III COMMANDS trial that were presented at the 2023 ASCO Meeting.
Source: Blood Cancers TodayCategories: Latest Headlines, Partners & KOLsTweet-
ICYMI: In this video interview, @drsangeetmd of @SylvesterCancer/ @UMiamiHealth weighs in on data from the phase III COMMANDS trial presented by @garciamanero of @MDAndersonNews at #ASCO2023. 📺: https://t.co/PrCANXluC2 https://t.co/tB6GflY56b
-
Coming Thursday, 8/10: In the latest episode of The HemOnc Pulse, @tinabhatnagar01 of @WVUCancer sheds light on AML disparities research and more with host @chadinabhan. Sign up to get the latest news and podcast episodes delivered to your inbox: https://t.co/aEpyHK4buA https://t.co/pxY6wI4J7S